London: Advanced studies of AstraZeneca’s COVID-19 candidate vaccine are temporarily discontinued while the company examines whether a recipient’s “potentially unexplained” disease is a side effect of the shot.
In a statement, the company said its “standard review procedure caused a pause in vaccination to allow review of protection data. “
AstraZeneca did not reveal any facts about the imaginable side effects, unless she calls it “a potentially unexplained disease. “
Health news site STAT first reported the pause in testing, saying that the imaginable-looking effect had occurred in the UK. A spokesperson for AstraZeneca showed that the vaccination break covers studies in the United States and other countries.
Late last month, AstraZeneca began recruiting another 30,000 people in the United States for further vaccine study. It also tests the vaccine, developed through the University of Oxford, in thousands of others in Britain and in smaller studies in Brazil and South Africa. .